Am I Eligible for GLP-1 Medications?

GLP-1 medications have very specific eligibility criteria set by the FDA. More people qualify than commonly think. Eligibility depends on your BMI, existing health conditions, and whether you're seeking treatment for weight management or type 2 diabetes. Understanding these criteria can help you determine whether GLP-1 therapy might be right for you.

Understanding BMI and Eligibility Thresholds

Body Mass Index (BMI) is the primary eligibility metric for GLP-1 medications approved for chronic weight management. BMI is calculated by dividing your weight in kilograms by your height in meters squared. According to FDA guidance, adult eligibility begins at:

To calculate your BMI, you can use your weight in pounds and height in inches with this formula: (weight ÷ height²) × 703. For example, a 5'9" person weighing 220 pounds has a BMI of about 32.5.

Important BMI limitations: While BMI is a useful screening tool, it has significant limitations. BMI doesn't distinguish between muscle and fat—athletes or very muscular individuals may have high BMI without excess body fat. Conversely, some people classified as "normal weight" may carry excess fat around vital organs (visceral fat), which carries metabolic risk. Additionally, some populations—including certain ethnic groups and older adults—may have elevated health risks at lower BMI thresholds than the standard cutoffs suggest. Your doctor should assess your overall health picture, not BMI alone.

Qualifying Conditions: Detailed Criteria

If your BMI falls between 27–29.9, you can qualify with one of these weight-related conditions:

Type 2 Diabetes: Special Eligibility Rules

If you have type 2 diabetes, GLP-1 medications like semaglutide (Ozempic, Rybelsus), tirzepatide (Mounjaro, Zepbound), and dulaglutide (Trulicity) are FDA-approved for glycemic control regardless of BMI. This means you can qualify for GLP-1 therapy even if your BMI is below 27. Many endocrinologists and primary care doctors prescribe GLP-1s as second-line agents after metformin, especially if you have overweight/obesity alongside your diabetes diagnosis. The American Diabetes Association now includes GLP-1 RAs in its recommended treatment algorithm, recognizing both glucose-lowering and cardiovascular benefits.

Off-Label Prescribing: When Doctors Prescribe Below FDA Thresholds

Some doctors prescribe GLP-1 medications to patients with BMI below the FDA-approved thresholds, a practice called off-label prescribing. This is legal and relatively common in clinical practice. Off-label prescribing often occurs when a patient has metabolic syndrome—a cluster of conditions including insulin resistance, abdominal obesity, elevated blood pressure, and dyslipidemia—even if they don't meet a single condition's threshold independently.

However, there's an important caveat: insurance companies typically will not cover off-label prescribing. If your doctor prescribes a GLP-1 below the BMI/condition criteria, your claim may be denied, and you'll be responsible for the full cost. This is where self-pay programs become relevant. Telehealth companies offering direct-to-consumer GLP-1 therapy (without insurance) generally stick to FDA criteria to minimize prescribing risk, though some may have slightly different standards.

Insurance vs. Self-Pay Eligibility: Know the Difference

Insurance coverage typically requires meeting strict FDA criteria, but many health plans also impose additional hurdles:

• Prior authorization (PA): Your doctor must submit medical records and justify the prescription before you can fill it. This can take 3–7 business days.
• Step therapy (fail-first): Some plans require proof that you've tried and failed conventional weight-loss treatments (diet, exercise, sometimes other medications like phentermine) before approving GLP-1s. This can add weeks to the process.
• Documented diet attempts: Insurers often request records of medically supervised weight-loss efforts or at least documented attempts at lifestyle modification.
• BMI or condition thresholds higher than FDA: Some commercial plans use BMI ≥ 35 as a threshold, or require two qualifying conditions, making eligibility more restrictive than the FDA label allows.

Self-pay telehealth programs (direct-to-consumer services) typically follow FDA criteria more closely and skip the authorization process. You have a single online visit with a provider, they assess your eligibility based on your self-reported BMI and health history, and if approved, they send a prescription to a pharmacy or provide it directly. Self-pay eliminates prior authorization delays but comes at full out-of-pocket cost—usually $200–$500/month depending on medication and dosage.

Who Should NOT Take GLP-1 Medications: Contraindications

Relative contraindications (use with caution): Your doctor may recommend against GLP-1s or monitor you closely if you have:

• History of pancreatitis: GLP-1 medications can theoretically increase pancreatitis risk. If you've had acute or chronic pancreatitis, benefits must be weighed against this risk.
• Severe gastroparesis: GLP-1s slow gastric emptying, which can worsen existing gastroparesis and cause severe nausea, vomiting, or obstruction.
• Severe kidney disease (eGFR < 15 mL/min): Some GLP-1s require dose adjustment or careful monitoring in advanced renal failure.
• Severe liver disease (Child-Pugh class C): Limited safety data in cirrhosis; careful monitoring required.
• Eating disorders or disordered eating patterns: GLP-1 medications can suppress appetite, potentially worsening restrictive eating patterns or enabling eating disorder behaviors in susceptible individuals.
• Recent or active thyroid nodules: GLP-1s may stimulate thyroid C-cell growth; baseline ultrasound and monitoring may be recommended.
• Certain drug interactions: GLP-1s slow gastric emptying and may affect the absorption of oral medications, including oral contraceptives and some antibiotics.

Pediatric Eligibility: Children and Adolescents

Two GLP-1 medications are FDA-approved for pediatric weight management:

• Semaglutide (Wegovy): Approved for ages 12 and older with BMI ≥ 95th percentile for age and sex (obesity in pediatric terms).
• Liraglutide (Saxenda): Approved for ages 12 and older with BMI ≥ 95th percentile for age and sex.

Children under 12 are not yet approved for GLP-1 weight-management therapy, though some pediatric endocrinologists use off-label GLP-1 RAs (like semaglutide or GLP-1/GIP combinations) for severe obesity with comorbidities. The American Academy of Pediatrics continues to gather safety and efficacy data in this age group.

The Evaluation and Intake Process

Getting evaluated for GLP-1 therapy typically follows one of two paths: through your primary care doctor or via a telehealth program. Here's what to expect:

Path 1: Primary Care Evaluation

1. Schedule an appointment: Call your doctor's office and ask for a "weight management consultation" or "GLP-1 evaluation." Many insurers cover office visits if you mention metabolic risk factors.
2. Bring your health history: Have details ready about past weight-loss attempts, family history of diabetes or heart disease, current medications, and any surgeries.
3. Biometric screening: The doctor will measure your height and weight to calculate BMI, check blood pressure, and possibly order bloodwork (glucose, A1C, lipid panel, kidney and liver function).
4. Discussion of risks and benefits: Your doctor will review why GLP-1 might help, potential side effects (nausea, vomiting, constipation, rare pancreatitis risk), cost/insurance coverage, and lifestyle expectations (diet and exercise still matter).
5. Prescription and pharmacy coordination: If approved, your doctor sends a prescription to your pharmacy or makes a referral to a weight-management specialist. Insurance may require prior authorization (3–7 days).
6. Follow-up monitoring: Most doctors schedule follow-ups every 4–8 weeks to assess side effects, weight loss, and dose tolerance.

Path 2: Telehealth Program Intake

1. Online intake form: You fill out a questionnaire with your height, weight, blood pressure, and health history. Most ask about past medical conditions, current medications, and weight-loss history.
2. Video consultation (typically 20–40 minutes): A nurse practitioner or physician assistant reviews your form, asks clarifying questions, and may request recent bloodwork (many programs accept results from your primary doctor; some require you to order labs through their partner lab).
3. Eligibility decision: On the same call or within 24 hours, you're notified whether you qualify. If approved, the provider discusses medication options, starting dose, cost, and side effect management.
4. Prescription delivery: Your prescription is sent to a pharmacy of your choice (usually CVS, Walgreens, or Rite Aid) or shipped directly from the program's partner pharmacy. Some programs use compounded semaglutide or other GLP-1s.
5. Ongoing telehealth check-ins: Most programs schedule virtual visits every 4 weeks to adjust dosage, address side effects, and track progress. Some programs include coaching calls with nutritionists.

Labs and Testing

Common labs ordered before starting GLP-1 therapy include:

• Fasting glucose or hemoglobin A1C (to screen for prediabetes or diabetes)
• Lipid panel (cholesterol, triglycerides)
• Creatinine and eGFR (kidney function)
• ALT and AST (liver function)
• Thyroid-stimulating hormone (TSH) and possibly thyroid ultrasound (given MTC risk considerations)
• Calcitonin (optional baseline in some programs; to establish thyroid C-cell baseline)

Timeline: Once you're approved, expect 5–14 days to receive your first dose (accounting for pharmacy fulfillment and shipping). Most programs support starting at the lowest available dose (0.25 mg of semaglutide) with gradual weekly increases to minimize nausea.

Dose Titration and Maintenance

GLP-1 medications are not prescribed at a fixed dose. Instead, your dose typically increases every week or every few weeks until you reach a therapeutic dose or side effects become limiting. Semaglutide (Wegovy) typically starts at 0.25 mg and increases to a maintenance of 2.4 mg once weekly. Tirzepatide (Zepbound) starts at 2.5 mg and escalates to a maximum of 15 mg. Your provider will work with you to find the dose that balances weight loss with tolerability.

Citations and Authority

References:

• FDA approval letters for semaglutide (Wegovy) and tirzepatide (Zepbound) weight-management indications
• American Diabetes Association: Standards of Care in Diabetes (2024 edition) — GLP-1 RA use in type 2 diabetes
• Endocrine Society Clinical Practice Guideline: Pharmacologic Management of Obesity (2017, updated recommendations)
• FDA pregnancy and lactation labeling rule (PLLR) contraindications for GLP-1 agonists
• NIH definition and clinical significance of BMI limitations in cardiovascular risk assessment
• American Academy of Pediatrics: Obesity in Children and Adolescents (2023 guidelines on GLP-1 use in youth)